<![CDATA[GLP-1 RAs Linked to Lower Mortality, Amputation Risk in Patients With PAD and Type 2 Diabetes]]>

GLP-1 Receptor Agonists Linked to Lower Mortality, Amputation Rate in PAD and Type 2 Diabetes

Can GLP-1 medications improve health in people with Type 2 diabetes and PAD?

Research Highlights: GLP-1RA (glucagon-like peptide-1 receptor agonist) medications, which are prescribed to treat Type 2 diabetes and to he

Study: GLP-1 drugs like semaglutide linked to lower amputation risk in diabetes patients with peripheral artery disease

A new study suggests GLP-1 medications, such as semaglutide, were associated with better overall outcomes in people with type 2 diabetes and

GLP-1 Receptor Agonists Linked to Small Risk of Smell and Taste Disturbances in Type 2 Diabetes

The absolute risk appears low, but new data suggest small changes in smell and taste with GLP-1 treatment may exceed those already associate

Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us

Explore the real-world impact: A study analyzed 17,267 T2D adults on GLP-1 RAs, revealing downstream health effects with electronic health r

National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities

This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis and practical consider